{"entity":{"id":"nct00576914","kind":"trial","name":"Adjuvant Vinorelbine Plus Cisplatin (NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer","aka":[],"tldr":"A phase 3 trial of Recombinant human endostatin in Non-small-cell lung cancer, run by Chinese Academy of Sciences, with a status the registry has not verified recently.","summary":"Adjuvant Vinorelbine Plus Cisplatin (NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer is a phase 3 interventional study registered as NCT00576914 by Chinese Academy of Sciences, with 1108 participants planned, started 2007-06 and due to reach its primary completion in 2012-06. Interventions recorded: recombinant human endostatin. Conditions recorded: Non-small Cell Lung Cancer.\n\nLinked to the drug Recombinant human endostatin because the registry names it among its interventions and Non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT00576914","url":"https://clinicaltrials.gov/study/NCT00576914"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","resectable-nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["recombinant-human-endostatin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT00576914","phase":"3","setting":"Adjuvant Vinorelbine Plus Cisplatin Versus Vinorelbine Plus Cisplatin Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer (Phase III Study, Randomized, Open, Multi-center)","sponsor":"Chinese Academy of Sciences","participation":[{"nct":"NCT00576914","source":"https://clinicaltrials.gov/study/NCT00576914","fetchedAt":"2026-10-07T16:52:08.840Z","studySha256":"82192732655f57287b43e2c35a822a1a72b2ca7469a0778e4971c31ccb15a8d4","overallStatus":"UNKNOWN","lastUpdatePosted":"2010-03-09","leadSponsor":"Chinese Academy of Sciences","collaboratorCount":3,"minimumAge":"18 Years","maximumAge":"70 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":1108,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2007-06","enrolled":1108,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct00576914/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/"}],"drug":[{"id":"recombinant-human-endostatin","kind":"drug","name":"Recombinant human endostatin","route":"/drugs/recombinant-human-endostatin/"}]}}